mebendazole has been researched along with Colorectal Neoplasms in 1 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mebendazole was well tolerated and its addition to bevacizumab and FOLFOX4 enhanced tumor response to treatment which was translated by significant improvement of overall response rate 12 weeks after intervention [10 % (2) versus 65% (13) for control and mebendazole groups, respectively; p = 0." | 7.11 | Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. ( El-Azab, GA; El-Ghoneimy, RA; Hegazy, SK; Mostafa, MF; Zakaria, F, 2022) |
| "Mebendazole was well tolerated and its addition to bevacizumab and FOLFOX4 enhanced tumor response to treatment which was translated by significant improvement of overall response rate 12 weeks after intervention [10 % (2) versus 65% (13) for control and mebendazole groups, respectively; p = 0." | 3.11 | Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. ( El-Azab, GA; El-Ghoneimy, RA; Hegazy, SK; Mostafa, MF; Zakaria, F, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hegazy, SK | 1 |
| El-Azab, GA | 1 |
| Zakaria, F | 1 |
| Mostafa, MF | 1 |
| El-Ghoneimy, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer[NCT03925662] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mebendazole and Colorectal Neoplasms
| Article | Year |
|---|---|
Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2022 |